Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological changes in glioblastoma multiforme patients treated with bevacizumab (Phase IV, non-interventional)
2024-512136-30-00Phase 4Authorised
- Sponsor
- Országos Onkológiai Intézet
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in glioblastoma (GBM), sponsored by Országos Onkológiai Intézet. Primary endpoints: Immunological changes during disease course and bevacizumab treatment, Local relapse-free survival and 2 more. Planned start Jun 2024; status: authorised.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-512136-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512136-30-00.